Skip to content

US · TRVI · BIOTECHNOLOGY

Trevi Therapeutics, Inc. (TRVI) intrinsic value and stock valuation

$13.35as of 2026-11-21 · Mkt cap 2.63B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Trevi Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TRVI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TRVI’s statements →

Trevi Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New Haven, CT 06510 trevitherapeutics.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$0.00
20162025
Net income
-$-42.76M
20162025
Free cash flow
-$-42.1M
20162025
Total equity
$183.2M+46.4% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-49.33M-$-51.52M-$-33.92M-$-29.91M-$-32.48M
Net income-$-42.76M-$-47.91M-$-29.07M-$-29.15M-$-33.94M
EPSd-$-294.69K-$-474.17K-$-293.55K-$-451.66K-$-1.49M
Operating cash flow-$-42.09M-$-38.26M-$-31.71M-$-28.18M-$-28.95M
Capital expenditure-$-10K-$-40K-$-140K-$-160K$0.00
Free cash flow-$-42.1M-$-38.29M-$-31.85M-$-28.33M-$-28.95M
Total assets$193.4M$110.9M$89.4M$123M$38.5M
Total debt$750K$1.03M$1.34M$9.18M$14.6M
Net debt-$-18.16M-$-33.06M-$-31.06M-$-3.41M-$-22.2M
Total equity$183.2M$99.6M$82.6M$107.5M$17.1M
Cash and short-term investments$188.3M$107.6M$83M$120.5M$36.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$33.5M$39.4M$23.7M$19.8M$23M
Selling, general and administrative expenses$15.9M$12.2M$10.2M$10.1M$9.49M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$49.3M$51.5M$33.9M$29.9M$32.5M
Cost and expenses$49.3M$51.5M$33.9M$29.9M$32.5M
Interest income$6.54M$3.6M$4.75M$1.74M$10K
Interest expense$0.00$0.00$390K$780K$1.2M
Depreciation and amortization$140K$150K$120K$40K$50K
Ebitda-$-42.68M-$-47.79M-$-28.58M-$-27.98M-$-32.71M
Operating income-$-49.33M-$-51.52M-$-33.92M-$-29.91M-$-32.48M
Total other income/expenses, net$6.5M$3.58M$4.83M$720K-$-1.49M
Income before tax-$-42.82M-$-47.94M-$-29.1M-$-29.19M-$-33.96M
Income tax expense-$-60K-$-30K-$-30K-$-40K-$-20K
Net income-$-42.76M-$-47.91M-$-29.07M-$-29.15M-$-33.94M
Weighted average shares outstanding$145.1M$101M$99M$64.5M$22.8M
Weighted average diluted shares outstanding$145.1M$101M$99M$64.5M$22.8M
Balance sheet
20252024202320222021
Cash and short-term investments$188.3M$107.6M$83M$120.5M$36.8M
Net receivables$990K$530K$0.00$0.00$240K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$191.7M$109.4M$87.6M$122.6M$38M
Property, plant and equipment, net$850K$1.23M$1.56M$190K$180K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.78M$1.47M$1.86M$400K$520K
Total assets$193.4M$110.9M$89.4M$123M$38.5M
Accounts payable$3.91M$3.41M$1.81M$2.86M$2.85M
Short-term debt$310K$280K$310K$7.03M$5.95M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.75M$10.5M$5.82M$13.4M$12.7M
Long-term debt$450K$750K$1.03M$2.15M$8.68M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$450K$750K$1.03M$2.16M$8.68M
Capital lease obligations$750K$1.03M$1.34M$30K$140K
Total liabilities$10.2M$11.3M$6.86M$15.6M$21.4M
Common stock$130K$90K$70K$60K$30K
Retained earnings-$-329.8M-$-287.05M-$-239.13M-$-210.07M-$-180.92M
Accumulated other comprehensive income (loss)$150K$60K-$-30K-$-120K$0.00
Total equity$183.2M$99.6M$82.6M$107.5M$17.1M
Total investments$169.4M$73.5M$50.6M$107.9M$0.00
Total debt$750K$1.03M$1.34M$9.18M$14.6M
Net debt-$-18.16M-$-33.06M-$-31.06M-$-3.41M-$-22.2M
Cash flow statement
20252024202320222021
Net income-$-42.76M-$-47.91M-$-29.07M-$-29.15M-$-33.94M
Depreciation and amortization$140K$150K$120K$40K$50K
Stock-based compensation$5.18M$3.59M$2.25M$2.33M$2.54M
Change in working capital-$-3.49M$6.83M-$-3.85M-$-1.23M$1.51M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-600K$1.6M-$-1.05M$10K$830K
Net cash provided by operating activities-$-42.09M-$-38.26M-$-31.71M-$-28.18M-$-28.95M
Investments in property, plant and equipment-$-10K-$-40K-$-140K-$-160K$0.00
Acquisitions, net$0.00$0.00$0.00-$-830K$0.00
Net cash used for investing activities-$-94.11M-$-21.53M$59.4M-$-107.37M$0.00
Common stock issued$120.3M$61.2M$1.71M$105.4M$21.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$121M$61.5M-$-7.91M$111.3M$20.8M
Net change in cash-$-15.18M$1.7M$19.8M-$-24.24M-$-8.17M
Cash at end of period$18.9M$34.1M$32.4M$12.6M$36.8M
Operating cash flow-$-42.09M-$-38.26M-$-31.71M-$-28.18M-$-28.95M
Capital expenditure-$-10K-$-40K-$-140K-$-160K$0.00
Free cash flow-$-42.1M-$-38.29M-$-31.85M-$-28.33M-$-28.95M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Trevi Therapeutics, Inc.

        Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

        CEO
        Jennifer L. Good
        Employees
        34
        Beta
        1.00

        Explore

        Frequently asked questions

        What is the intrinsic value of Trevi Therapeutics, Inc. (TRVI)?

        InvestorsCraft does not currently publish an intrinsic value for TRVI. How the IC value is calculated.

        Is TRVI undervalued?

        InvestorsCraft does not publish an undervaluation signal for TRVI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.